Literature DB >> 25640055

NFATc1 deletion in T lymphocytes inhibits the allergic trait in a murine model of asthma.

S Koch1, S Reppert1, S Finotto1.   

Abstract

BACKGROUND: NFATc1 isoforms are highly regulated in peripheral T cells where they contribute to the effector function and cell homeostasis.
OBJECTIVE: Here, we investigated the role of NFATc1 in asthma and in T cells.
METHODS: In a murine model of allergic asthma, we analysed differences in T-cell development in this allergic disease model, between wild-type and NFATc1 conditional knockout mice. Thus, we performed quantitative real-time PCR to investigate the mRNA expression of Th2-associated genes as well as genes that are involved in IgE immunoglobulin class-switch. Additionally, we used ELISA, Western blot and flow cytometry (FACS) to analyse protein concentrations of Th1-, Th2- and Th17-specific transcription factors and cytokines and the Th2 chemokine, thymus and activation-regulated chemokine/chemokine ligand 17 (TARC/CCL17) by ELISA.
RESULTS: Mice lacking NFATc1 in CD4(+) T cells display a significant reduction in lung Th2 and Th17 as well as an increase of Th1 cells in an experimental asthma model. Additionally, Batf gene, a recently described transcription factor of the Th2 and Th17 cell differentiation as well as a key T and B transcription factor involved in the IgE immunoglobulin class-switch, was found decreased in the lungs of these mice. As a consequence, serum OVA-specific IgE and IgG1 levels were found significantly decreased after allergen exposure and in the absence of NFATc1 in T cells in experimental allergic asthma. CONCLUSIONS AND CLINICAL RELEVANCE: Targeting NFATc1 in T lymphocytes ameliorated the allergic trait in the airways of NFATc1(fl/fl) xCD4Cre mice. NFATc1 emerges as a novel target for anti-allergy intervention.
© 2015 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IgE; NFATc1; T cells; allergic asthma; atopy

Mesh:

Substances:

Year:  2015        PMID: 25640055     DOI: 10.1111/cea.12493

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  7 in total

Review 1.  Th9 and other IL-9-producing cells in allergic asthma.

Authors:  Sonja Koch; Nina Sopel; Susetta Finotto
Journal:  Semin Immunopathol       Date:  2016-11-17       Impact factor: 9.623

2.  Acute 4,4'-Methylene Diphenyl Diisocyanate Exposure-Mediated Downregulation of miR-206-3p and miR-381-3p Activates Inducible Nitric Oxide Synthase Transcription by Targeting Calcineurin/NFAT Signaling in Macrophages.

Authors:  Chen-Chung Lin; Brandon F Law; Justin M Hettick
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

3.  Nuclear factor-κB mediates the phenotype switching of airway smooth muscle cells in a murine asthma model.

Authors:  Chen Qiu; Jian Zhang; Meiping Su; Xiujun Fan
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 4.  NFAT control of immune function: New Frontiers for an Abiding Trooper.

Authors:  Martin Vaeth; Stefan Feske
Journal:  F1000Res       Date:  2018-03-02

5.  Protein kinase 2 (CK2) controls CD4+ T cell effector function in the pathogenesis of colitis.

Authors:  Wei Yang; Sara A Gibson; Zhaoqi Yan; Hairong Wei; Jiahui Tao; Bingdong Sha; Hongwei Qin; Etty N Benveniste
Journal:  Mucosal Immunol       Date:  2020-01-27       Impact factor: 7.313

6.  IL-33/ST2/IL-9/IL-9R signaling disrupts ocular surface barrier in allergic inflammation.

Authors:  Jiaoyue Hu; Ning Gao; Yun Zhang; Xin Chen; Jinmiao Li; Fang Bian; Wei Chi; Zuguo Liu; Cintia S de Paiva; Stephen C Pflugfelder; De-Quan Li
Journal:  Mucosal Immunol       Date:  2020-05-01       Impact factor: 7.313

7.  Increased expression of nuclear factor of activated T cells 1 drives IL-9-mediated allergic asthma.

Authors:  Sonja Koch; Anna Graser; Hooman Mirzakhani; Theodor Zimmermann; Volker O Melichar; Marco Wölfel; Damien C Croteau-Chonka; Benjamin A Raby; Scott T Weiss; Susetta Finotto
Journal:  J Allergy Clin Immunol       Date:  2016-03-15       Impact factor: 10.793

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.